Immutep Set to Reveal TACTI-004 Trial Insights at WCLC 2025
Immutep Limited (ASX: IMM; NASDAQ: IMMP) is excited to announce its upcoming participation in the highly anticipated IASLC 2025 World Conference on Lung Cancer. This year, the focus will be on the pivotal TACTI-004 Phase III trial, a key study addressing non-small cell lung cancer (NSCLC). The conference will convene in Barcelona, Spain, bringing together leading experts in lung cancer treatment for discussions and presentations.
Highlights from the TACTI-004 Trial Presentation
The TACTI-004 trial presentation will showcase the innovative approach of combining eftilagimod alfa, a proprietary antigen presenting cell (APC) activator developed by Immutep, with chemotherapy and the renowned anti-PD-1 therapy KEYTRUDA®. This combination aims to enhance response rates for patients with advanced or metastatic NSCLC, addressing a critical need in cancer treatment.
This global trial plans to enroll around 750 patients and will be conducted at over 150 clinical sites across more than 25 countries, making it one of the significant studies in this domain that allows participation from patients regardless of their PD-L1 expression levels.
Immutep's Commitment to Advancing Cancer Therapies
Dr. Stephan Winckels, CMO of Immutep, has articulated the promising feedback received thus far from oncologists and medical professionals during prior engagements. These discussions reflect a growing consensus on the safety and efficacy of eftilagimod alfa, a notable advancement in immunotherapy treatments for cancer.
“We are eager to share our findings and gather further insights from our colleagues in the lung cancer research community at this significant conference. TACTI-004 has the potential to transform first-line treatment approaches for NSCLC patients,” he emphasized.
Details of the Poster Presentation at WCLC 2025
During the conference, the poster presentation will detail:
- Title: TACTI-004, a Phase 3 trial of Eftilagimod Alfa plus Pembrolizumab + Chemotherapy vs Placebo + Pembrolizumab + Chemotherapy in first-line NSCLC
- Presenter: Dr. Martin Sebastian from the University Hospital of Frankfurt, Germany
- Session: Clinical Trials in Progress
- Date and Time: Tuesday, 9 September 2025, at 10:00 AM CEST
This presentation will be available for viewing on Immutep's official website following its debut at the conference.
About Eftilagimod Alfa (efti)
Efti is Immutep’s flagship product designed to stimulate the immune system. It functions as a soluble LAG-3 protein that enhances antigen presentation, which plays a crucial role in immune activation. This mechanism is pivotal in the fight against cancer, as it aims to activate various immune cell types like CD8+ T cells and dendritic cells to combat tumor growth.
Under clinical evaluation for multiple solid tumors, including NSCLC and breast cancer, efti has already shown considerable promise by achieving Fast Track designation from the FDA for first-line treatments in NSCLC and head and neck cancers, indicating its significance in oncological advances.
About Immutep
Immutep, a cutting-edge biotechnology company, is devoted to developing transformative immunotherapeutic options for cancer and autoimmune diseases. With a strong emphasis on LAG-3 biology, the company is paving the way for new therapies that may offer hope to patients dealing with challenging diagnoses.
For those interested in exploring more about Immutep and its innovative approaches, more information can be found on their official website.
Frequently Asked Questions
1. What is the purpose of the TACTI-004 trial?
The TACTI-004 trial aims to evaluate the efficacy of eftilagimod alfa combined with chemotherapy and KEYTRUDA® for patients with advanced or metastatic non-small cell lung cancer.
2. Who will be presenting the trial findings?
Dr. Martin Sebastian from the University Hospital of Frankfurt will present the findings during the conference.
3. When is the IASLC 2025 World Conference on Lung Cancer being held?
The conference will take place from September 6 to September 9, 2025, in Barcelona, Spain.
4. What is efti and how does it work?
Efti is an APC activator that stimulates the immune system to enhance the body's ability to fight cancer by activating various immune cells.
5. How can I find more information about Immutep?
For additional details about Immutep and its projects, you can visit their official website.
